FEATURES OF THE CLINICAL PICTURE AND ANTHROPOMETRIC INDICES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i2.8687Keywords:
non-alcoholic fatty liver disease, pre-diabet, type 2 diabetes mellitus.Abstract
The work is devoted to the study of the features of the clinical picture of nonalcoholic steatosis and steatohepatitis in patients with pre-diabetes and type 2 diabetes mellitus (DM). A survey of 117 patients with a background of NADH and pre-diabetes and type 2 diabetes was performed. The prevalence of non-alcoholic steatosis and steatohepatitis in patients with pre-diabetes was studied. It has been shown that patients with NAGHP and pre-diabetes should be classified as very high cardiovascular risk (CD). The peculiarities of carbohydrate and lipid metabolism in patients with NADH on the background of pre-diabetes and type 2 diabetes were studied.
Material and Methods. This work reflects the results of a comprehensive survey of 141 patients with type 2 diabetes and pre-diabetes.
Results. The leading symptoms in patients with NADH are nausea, pain, flatulence and stomach upsets. Significant differences between patients in groups I and II were detected only with complaints such as: flatulence, general weakness, sense of bitterness in the oral cavity and nausea.
Conclusions NSCLC was diagnosed in 98.4 % of patients with type 2 diabetes, including steatosis in 54.84 %, and steatohepatitis in 45.16 %. In persons with pre-diabetic NADH, 70.5 % were established, of which 85.45 % were steatosis and 14.55 % were steatohepatitis (p<0.05). The features of the clinical picture of NADH are oligosymptomy, comorbidity and the predominance of dyspeptic syndrome (flatulence was found in 43.59 %, pain in the right hypochondrium and discomfort in the abdominal cavity – 29.91 % and 28.21 % respectively, and a feeling of bitterness in the oral cavity – by 21.37 %).
References
Fadieienko, H.D., & Chernyshov, V.A. (2014). Komorbidna patolohiia, shcho vplyvaie na sertsevo-sudynnyi ryzyk u postinfarktnykh khvorykh [The comorbid pathology influencing cardiovascular risk in post-arthritis patients]. Ukrainskyi terapevtychnyi zhurnal – Ukrainian Therapeutic Journal, 2, 10-20 [in Ukrainian].
Babak, O.Ya., & Lapshina, E.A. (2016). Lechebnaya taktika u patsyentov s nealkogolnoy zhyrovoy boleznyu pecheni s uchetom urovnya tsytokeratina-18 v plazme krovi [Therapeutic tactics in patients with non-alcoholic fatty liver disease taking into account the level of cytokeratin-18 in blood plasma]. Suchasna hastroenterolohiia – Modern Gastroenterology, 2, 15-20 [in Russian].
Stepanov, Yu.M., Chukhrienko, N.D., & Salenko, A.V. (2015). Otsinka efektyvnosti hepatoprotektora Hepa Veda u khvorykh iz patolohiieiu pechinky [Evaluation of the effectiveness of hepatoprotector Gep Veda in patients with liver pathology]. Hastroenterolohiia – Gastroenterology, 2, 29-32 [in Ukrainian].
Hukhlina, O.S., Mandryk, O.E., & Antoniv, A.A. (2013). Stan fibrozuvannia pechinky ta yoho naslidky u khvorykh na nealkoholnyi steatohepatyt iz komorbidnym ozhyrinniam ta hipertonichnoiu khvoroboiu u dynamitsi likuvannia preparatamy Hepadyf, Ezetymib ta Fozynopryl [The state of liver fibrosis and its consequences in patients with non-alcoholic steatohepatitis with comorbid obesity and hypertension in the dynamics of treatment with the drugs Hepadif, Ezetimib and Phosinopril]. Novosti meditsiny i farmatsii – News of Medicine and Pharmacy, 451, 24-26 [in Ukrainian].
Chernyavskiy, V.V. (2011). Zhirovaya bolezn pecheni kak integralnaya problema vnutrenney meditsiny [Fatty liver disease as an integral problem of internal medicine]. Novosti meditsiny i farmatsii – News of Medicine and Pharmacy, 4, 354 [in Russian].
Pankiv, V.I. (2012). Piohlitazon: rozdumy pro realnist i perspektyvy vykorystannia [Pioglitazone: Reflections on the reality and perspectives of use]. Mizhnarodnyi endokrynolohichnyi zhurnal – International Endocrinology Journal, 1, 69-73 [in Ukrainian].
Kovalenko, V.M. (2010). Kalkuliator kardiovaskuliarnoho ryzyku [Cardiovascular risk calculator]. Zdorovia Ukrainy – Health of Ukraine, 3, 6 [in Ukrainian].
Sirenko, Yu.M. (2011). Hipertonichna khvoroba i arterialni hipertenzii [Hypertonic disease and arterial hypertension]. Donetsk [in Ukrainian].
Kolesnikova, O.V., Babak, O.Ya., & Solomenseva, T.A. (2013). Osoblyvosti vuhlevodnoho ta lipidnoho obminu u khvorykh na nealkoholnu zhyrovu khvorobu pechinky zalezhno vid stupenia kardiovaskuliarnoho ryzyku [Features of carbohydrate and lipid metabolism in patients with nonalcoholic fatty liver disease depending on the degree of cardiovascular risk]. Suchasna hastroenterolohiia – Modern Gastroenterology, 6, 7-12 [in Ukrainian].
Kharchenko, N.V., Khobzei, M.K., & Lishchyshyna, A.M. (2014). Unifikovanyi klinichnyi protokol “Nealkoholnyi steatohepatyt” [Unified clinical protocol "Non-alcoholic steatohepatitis"]. Nakaz MOZ Ukrainy № 826 – The Order of the Ministry of Health of Ukraine No. 826 [in Ukrainian].
Shevchuk, V.V., & Fediv, O.I. (2013). Zminy oksydantno-protyoksydantnoho homeostazu pry nealkoholnomu steatohepatyti u khvorykh z metabolichnym syndromom [Changes of oxidant-antioxidant homeostasis in non-alcoholic steatohepatitis in patients with metabolic syndrome]. Visnyk problem biolohii i medytsyny – Bulletin of Biological and Medical Problems, 3 (1), 276-279 [in Ukrainian].
Lutay, M.I. (2016). Effektivnost statinoterapii: dokazatelnaya meditsyna i realnaya klinicheskaya praktika [The efficacy of statin therapy: evidence-based medicine and real clinical practice]. Zdorovia Ukrainy. Kardiolohiia. Revmatolohiia. Kardiokhirurhiia – Health of Ukraine. Cardiology. Rheumatology Cardiac Surgery, 3 (46), 3 [in Russian].
Parkhomenko, O.M. (2016). Kardioprotektsiia pry ishemii miokarda. Mozhlyvosti ta perspektyvy [Cardiprotection at ischemia of the myocardium. Opportunities and prospects]. Naukovo-praktychna konferentsiia, prysviachena 140-richchiu vid dnia narodzhennia M. D. Strazheska – Scientific-Practical Conference devoted to the 140th anniversary of the birth of M. D. Strazhesko [in Ukrainian].
Malyshev, P.P., & Ivanov, K. (2010). Nealkogolnaya zhyrovaya bolezn pecheni: aspekty disgnostiki i lecheniya [Non-alcoholic fatty liver disease: aspects of diagnosis and treatment]. Sonsilium Medicum, Gastroenterologiya – Sonsilium Medicum, Gastroenterology, 2, 2 [in Russian].
Lazo, M., Solga, S., & Horska, A. (2010). Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care, 33, 2156-2163.
Keating, S.E., Hackett, D.A., & George, J. (2012). Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol., 57, 157-166.
Vernon, G., Baranova, A., & Younossi, Z.M. (2011). Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther., 34, 274-285.
Musso, G., Gambino, R., & Cassader, M. (2010). A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 52, 79-104.
Ratziu, V. (2009). A proposal for current and future therapeutic strategies for NASH: EASL Special Conference “NAFLD/NASH and Related Metabolic Disease” Bologna, Italy. Program and Abstracts, 29.
Maurantonio, M., Ballestri, S., & Odoardi, M.R. (2011). Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch. Med. Res., 42, 337-353.
